drugset / Trial / NCT07689175
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
Phase 2
Not yet recruiting
60 enrolled
University of Texas Southwestern Medical Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.
Timeline
- Start
- 2026-10-31
- Primary completion
- 2031-10-31
- Completion
- 2032-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |